<DOC>
	<DOC>NCT00126789</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety of the matrix fentanyl patch ZR-02-01 in providing relief of cancer pain.</brief_summary>
	<brief_title>Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain</brief_title>
	<detailed_description>This study will evaluate the safety of the matrix fentanyl patch. The study will be conducted in opioid-tolerant patients with moderate to severe cancer pain currently taking an around-the-clock opioid. Patients will discontinue their current opioid regimen and begin using ZR-02-01 as soon as possible under the direction of the physician investigator upon entry into the study. Patient's dose of ZR-02-01 will be determined by the investigator using sponsor-provided conversion. Pain therapy will be under the supervision of the physician investigator.</detailed_description>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Patient is at least 18 and no older than 75 years of age at the time of screening Patient has a diagnosis of cancer Patient has moderate to severe pain that is related to cancer or its treatment and is expected to last indefinitely and is currently taking an aroundtheclock opioid to treat his/her pain Patient is already receiving opioid therapy, has demonstrated opioid tolerance A responsible adult caregiver is available in the event of an emergency at home Patient has uncontrolled or rapidly escalating pain as determined by the investigator Patient has a history of substance abuse or has a substance abuse disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Pain Cancer</keyword>
	<keyword>Chronic Pain</keyword>
</DOC>